PMID- 28031898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2056-5623 (Print)
IS  - 2056-5623 (Electronic)
IS  - 2056-5623 (Linking)
VI  - 1
IP  - 3
DP  - 2015 Nov
TI  - Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising 
      target to treat and prevent these diseases.
PG  - FSO25
LID - 10.4155/fso.15.23 [doi]
LID - FSO25
AB  - The changes in the brain signaling systems play an important role in etiology and 
      pathogenesis of Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS), 
      being a possible cause of these diseases. Therefore, their restoration at the 
      early stages of T2DM and MS can be regarded as a promising way to treat and 
      prevent these diseases and their complications. The data on the functional state 
      of the brain signaling systems regulated by insulin, IGF-1, leptin, dopamine, 
      serotonin, melanocortins and glucagon-like peptide-1, in T2DM and MS, are 
      analyzed. The pharmacological approaches to restoration of these systems and 
      improvement of insulin sensitivity, energy expenditure, lipid metabolism, and to 
      prevent diabetic complications are discussed.
FAU - Shpakov, Alexander O
AU  - Shpakov AO
AD  - Laboratory of Molecular Endocrinology & Neurochemistry, I.M. Sechenov Institute 
      of Evolutionary Physiology & Biochemistry, Russian Academy of Sciences, Thorez 
      av. 44, 194223, St. Petersburg, Russia; Laboratory of Molecular Endocrinology & 
      Neurochemistry, I.M. Sechenov Institute of Evolutionary Physiology & 
      Biochemistry, Russian Academy of Sciences, Thorez av. 44, 194223, St. Petersburg, 
      Russia.
FAU - Derkach, Kira V
AU  - Derkach KV
AD  - Laboratory of Molecular Endocrinology & Neurochemistry, I.M. Sechenov Institute 
      of Evolutionary Physiology & Biochemistry, Russian Academy of Sciences, Thorez 
      av. 44, 194223, St. Petersburg, Russia; Laboratory of Molecular Endocrinology & 
      Neurochemistry, I.M. Sechenov Institute of Evolutionary Physiology & 
      Biochemistry, Russian Academy of Sciences, Thorez av. 44, 194223, St. Petersburg, 
      Russia.
FAU - Berstein, Lev M
AU  - Berstein LM
AD  - Laboratory of Oncoendocrinology, N.N. Petrov Research Institute of Oncology, St. 
      Petersburg, Russia; Laboratory of Oncoendocrinology, N.N. Petrov Research 
      Institute of Oncology, St. Petersburg, Russia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151101
PL  - England
TA  - Future Sci OA
JT  - Future science OA
JID - 101665030
PMC - PMC5137856
OTO - NOTNLM
OT  - brain
OT  - bromocryptine
OT  - diabetes mellitus
OT  - insulin
OT  - leptin
OT  - melanocortin
OT  - metabolic syndrome
OT  - neurodegeneration
OT  - signaling systems
OT  - treatment
COIS- Financial & competing interests disclosure This work was supported by the Russian 
      Science Foundation (project No 14-15-00413). The authors have no other relevant 
      affiliations or financial involvement with any organization or entity with a 
      financial interest in or financial conflict with the subject matter or materials 
      discussed in the manuscript apart from those disclosed. No writing assistance was 
      utilized in the production of this manuscript.
EDAT- 2016/12/30 06:00
MHDA- 2016/12/30 06:01
PMCR- 2015/11/01
CRDT- 2016/12/30 06:00
PHST- 2016/12/30 06:00 [entrez]
PHST- 2016/12/30 06:00 [pubmed]
PHST- 2016/12/30 06:01 [medline]
PHST- 2015/11/01 00:00 [pmc-release]
AID - 10.4155/fso.15.23 [doi]
PST - epublish
SO  - Future Sci OA. 2015 Nov 1;1(3):FSO25. doi: 10.4155/fso.15.23. eCollection 2015 
      Nov.